Trial Profile
A study to evaluate efficacy of Carfilzomib Pomalidomide and Dexamethasone in heavily pretreated patients with Relapsed/ Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Jan 2017
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 18 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology